Jun 20, 2023 Seladelpar Treatment Resulted in Correlated Decreases in Serum IL-31 and Pruritus in Patients With Primary Biliary Cholangitis (PBC): Post-hoc Results From the Phase 3 Randomized, Placebo-Controlled ENHANCE Study
Jun 20, 2023 Baseline Characteristics and Risk Profiles of 1111 Patients With Primary Biliary Cholangitis (PBC) in Need of Second-Line Therapy
Jun 20, 2023 Novel Pathways Implicated in the Seladelpar-mediated Reductions of Established Liver Fibrosis are Identified from RNAseq Data using Plex Search and Two Independent Mouse Pharmacology Datasets
Nov 5, 2022 Effects of single and multiple doses of the selective PPARĪ“ agonist seladelpar on diurnal markers of bile acid synthesis in mice
Nov 5, 2022 Seladelpar, a PPAR-delta agonist, improves inflammatory lipid mediators in the serum metabolome in patients with primary biliary cholangitis (PBC)
Nov 5, 2022 Seladelpar Improved the Lipid Profile of Patients With Primary Biliary Cholangitis (PBC): Results From Phase 2 and 3 Clinical Studies
Jun 25, 2022 The selective PPAR-delta agonist seladelpar (MBX-8025) suppresses bile acid synthesis by reducing hepatocyte CYP7A1 through the FGF21 pathway
Jun 21, 2022 Comparative fibroreducing activities of selected nuclear receptor agonists in the carbon tetrachloride mouse model
